39 results about "Bone marrow suppression" patented technology

The invention discloses a radix astragali, rhizoma polygonati and ligustrum lucidum ait traditional Chinese medicine preparation for treating myelosuppression as well as a preparation method and a detection method thereof. The preparation is prepared from 50-150 parts of radix astragali, 50-150 parts of wine-processed rhizoma polygonati, 25-75 parts of wine-processed ligustrum lucidum ait, 50-150 parts of blanched rhizoma drynariae, 50-150 parts of radix trichosanthis and 25-75 parts of herba epimedii. The optimal extraction process and refining process are screened out based on effective components and pharmacological activity through a large number of tests, and the optimal preparation process of the Shuanghuangliangwhitening oral liquid and other traditional Chinese medicine preparations is obtained through stability investigation and verification. According to the invention, a thin layer chromatography is adopted, the four medicinal materials of astragalus membranaceus, glossy privet fruit, rhizoma drynariae and herba epimedii are respectively subjected to thin layer chromatography research, and methodology research shows that the method is stable and feasible. The invention establishes a content determination method for astragaloside, calycosin-7-glucoside, specnuezhenide and icariin, establishes a quality standard, and has important significance for ensuring the clinical curative effect and safety of astragaloside, calycosin-7-glucoside, specnuezhenide and icariin.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and a use method, and belongs to the technical field of tumor immunotherapy. The invention formulates a non-small cell lung cancer weak chemotherapy and anti-vascular immunity triple treatment scheme based on the combination of a low-dose chemotherapy drug pemetrexed, an immune checkpoint inhibitor and an anti-angiogenesis drug. According to the scheme, low-dose pemetrexed is combined with the anti-angiogenesis medicine and the immune checkpoint inhibitor for use, the optimal synergistic effect can be achieved, meanwhile, the renal toxicity and the myelosuppression risk are remarkably reduced, and the pemetrexed medicine composition is expected to become one of the optimal choices for driving gene negative and PD-L1 positive expression non-squamous NSCLC patients, and has a wide application prospect. The device is suitable for old people or patients with poor physical states; especially for patients with negative driver genes and positive PD-L1 expression, the traditional treatment blank is filled, and clinical data shows that survival benefits are remarkable.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

The application discloses a high-safety tumor treatment preparation based on a prodrug-enzyme-neutralizing antibody three-system, and a preparation method and application thereof. The preparation comprises three core components: (a) a prodrug, which is coupled by an anti-tumor drug (such as doxorubicin) and cephalosporin; (b) an activating enzyme, such as beta-lactamase, which is specifically expressed in the tumor by phage, catalyzes the hydrolysis of the prodrug, and releases the active drug; and (c) a neutralizing antibody, such as an anti-doxorubicin monoclonal antibody, which can specifically bind and neutralize the active drug overflowing into the blood circulation. The application first integrates the precise killing strategy of "prodrug-local activation" and the safety strategy of "neutralizing antibody-systematic protection" into a complete treatment closed loop, utilizes the "differential neutralization" characteristics of the anti-doxorubicin antibody, effectively protects normal tissues from toxic damage under the premise of not affecting the local efficacy of the tumor, and significantly improves the therapeutic index of the chemotherapy drug, reduces the side effects such as cardiotoxicity and bone marrow suppression, and provides a new paradigm with high efficiency and safety for tumor treatment.

The invention relates to a medicinal and edible compound extract for improving myelosuppression of a tumor patient after chemotherapy, and a preparation method and application of the medicinal and edible compound extract. The compound extract is extracted from a composition at least comprising the following raw material medicines in parts by weight: 0.9-10 parts of tricholoma matsutake, 0.9-10 parts of mulberry and 0.5-10 parts of rhizoma polygonati. The raw material medicine composition further comprises the following raw material medicines in parts by weight: 0.7-10 parts of longan, 0.5-10 parts of pericarpium citri reticulatae, 0.5-10 parts of scorched hawthorn fruit, 0.5-10 parts of fructus amomi, 1.1-10 parts of cordyceps sinensis rice flour and 2.5-15 parts of rice peptide. The selected raw material medicines are all medicinal and edible components, do not cause adverse effects on liver and kidney functions and gastrointestinal tracts of eaters, and are high in safety and high in patient acceptance degree. Effect verification results show that the mulberry compound extract has an improvement effect on the side effect of bone marrow suppression of tumor patients, especially in the early stage, no related adverse reaction is found, and a safe and effective treatment choice is provided for bone marrow suppression.

The application discloses a chromone spiro compound, a preparation method and application thereof, and the chromone spiro compound is shown as formula I. The compound has selective CDK4 / 6 inhibitory activity, can relieve and / or treat myelosuppression caused by chemotherapy, improve weight loss caused by chemotherapy and improve survival rate, and has good drug safety. The compound has simple preparation method, is convenient for large-scale production, and has great application prospect.

The invention discloses a wolfberry-astragalus compound polysaccharide with an anti-myelosuppression effect as well as a preparation method and application of the wolfberry-astragalus compound polysaccharide. The wolfberry-astragalus compound polysaccharide is prepared by adopting a process of separately extracting wolfberry polysaccharide and astragalus polysaccharide and then mixing, the total sugar content is 70-80%, the uronic acid content is 10-14%, and the wolfberry-astragalus compound polysaccharide has specific molecular weight distribution and monosaccharide composition characteristics. Animal experiment results show that the wolfberry and astragalus compound polysaccharide can significantly improve peripheral hemopenia of myelosuppression mice induced by cyclophosphamide, promote recovery of the number of leukocytes, lymphocytes, monocytes and neutrophils, and effectively reverse weight loss caused by chemotherapeutic drugs. The wolfberry-astragalus compound polysaccharide provided by the invention is high in safety and remarkable in anti-myelosuppression effect, and can be used for preparing medicines or functional preparations for improving myelosuppression related diseases.

The invention relates to the technical field of pharmaceutical preparations, in particular to a traditional Chinese medicine composition for invigorating qi, blood, yin and yang and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials: tortoise-shell glue, deer-horn glue, donkey-hide gelatin, ginseng, astragalus membranaceus, codonopsis pilosula and fructus lycii, and is prepared by fermenting the raw materials, and the mass ratio of the tortoise-shell glue to the deer-horn glue to the donkey-hide gelatin to the ginseng to the astragalus membranaceus to the codonopsis pilosula to the fructus lycii is 1: (0.5-2): (0.5-2): (1-4): (2-5): (2-6): (2-6). The fermented product obtained by fermenting the medicine raw materials through probiotics can be used for treating qi-blood yin-yang deficiency syndromes such as fatigue, myocardial ischemia, cerebral hypoxia and kidney essence deficiency and / or treating and preventing leukopenia caused by myelosuppression and / or DNA (deoxyribonucleic acid) reduction after radiation and / or hypoimmunity and plateau hypoxia. The effects of preventing sudden cardiac death and the like are obvious.

The present invention relates to CARs that are specific for CD45, and cells comprising said CARs and their use in the treatment of disease, for example for myeloablation or for treating haematological cancer.

This invention discloses a yam vesicle nanomaterial, its preparation method, and its application for reducing the toxicity of radiotherapy for breast cancer. It belongs to the field of biomedical technology. The method includes adding PBS to the yam at a weight-to-volume ratio of 1:3 for juicing, sieving the yam juice, centrifuging the resulting yam filtrate at low speed to obtain supernatant A, centrifuging supernatant A at medium speed to obtain supernatant B, centrifuging supernatant B at ultra-high speed, resuspending the precipitate in PBS, and obtaining the yam vesicle nanomaterial. In this invention, the yam vesicle nanomaterial uses yam as raw material. The obtained yam vesicle nanomaterial has natural bone marrow targeting properties, requires no additional modification, and can spontaneously accumulate in the bone marrow after intravenous injection, specifically protecting the hematopoietic system. It can also simultaneously prevent the decrease in white blood cells, red blood cells, and platelets caused by radiotherapy, comprehensively alleviating the bone marrow suppression side effects of radiotherapy without affecting the efficacy of tumor radiotherapy.

The invention discloses application of bilobalide in inhibiting migration and invasion of ovarian cancer cells, and relates to the technical field of biological medicines. Application of bilobalide in preparation of drugs for inhibiting migration and invasion of ovarian cancer cells; the concentration of the bilobalide is 5 [mu] M to 40 [mu] M. In the application of the bilobalide, the bilobalide shows an obvious growth inhibition effect on ovarian cancer cells and has no obvious influence on the survival rate of normal ovarian cells; in a concentration range of 5-40 [mu] M, bilobalide shows dose dependence on activity inhibition of SKOV3 and ID-8 cells, but has small influence on IOSE80 cells, and shows a good safety window; compared with a traditional chemotherapeutic drug, the bilobalide as a natural compound has better biocompatibility, and is expected to be capable of remarkably relieving common toxic and side effects such as myelosuppression and liver and kidney function impairment in clinical application.

The invention discloses an anti-osteosarcoma combined pharmaceutical composition and application thereof. The combined pharmaceutical composition comprises a TNF alpha inhibitor and a chemotherapeutic drug. According to the invention, the TNF alpha inhibitor and the traditional chemotherapeutic drug are combined for use for the first time to resist osteosarcoma, so that the purposes of synergistic tumor inhibition, toxicity reduction and sensitization are achieved. By intervening a neglected chemotherapy side reaction pathway of tumor-liver axis, tumor-derived extracellular vesicles are blocked to induce Kupffer cells to release TNF alpha, liver lipid droplet deposition is reduced, and expression (including Cyp1a2, Cyp2b10, Cyp3a11 and the like) of CYP metabolic enzymes is recovered, so that the metabolic capability of the liver to chemotherapy drugs is improved, and toxic and side effects are reduced. From the perspective of chemotherapy tolerance and toxic and side effect control, cardiotoxicity and myelosuppression are remarkably reduced, the overall tolerance to a chemotherapy regimen is improved, and a safer and more efficient strategy is provided.

The invention discloses an application of a fresh astragalus source vesicle in preparation of chemotherapy adjuvant drugs. The invention provides and verifies that the fresh astragalus source vesicles have dual effects of enhancing the chemotherapy curative effect and relieving myelosuppression caused by chemotherapy for the first time, and can be used for a novel adjuvant therapy strategy. Meanwhile, the fresh radix astragali source vesicles are derived from medicinal and edible radix astragali, so that the fresh radix astragali source vesicles have the characteristics of high safety and low clinical risk, and a solid foundation is laid for subsequent clinical transformation.

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

The invention provides a spleen-tonifying and detoxifying traditional Chinese medicine composition as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises a formula A and a formula B. The traditional Chinese medicine composition has a comprehensive conditioning effect and can relieve chemotherapy side effects, improve intestinal flora distribution, promote intestinal health, enhance the chemotherapy effect and improve the disease control rate. Wherein the formula A focuses on tonifying spleen and regulating qi, and improving nausea, vomiting and other symptoms at the initial stage of chemotherapy, and the formula B is added with medicines for clearing away heat and toxic materials and promoting blood circulation to remove blood stasis on the basis, is suitable for patients with myelosuppression with cancer toxicity residue, and strengthens the effects of clearing away heat and toxic materials and removing stasis; the composition has a multi-target action mechanism, and through the combined action of multiple ways, the treatment effect is enhanced, and the side effect is reduced.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The application provides a derivative of plinabulin with the structure of formula (I), which is used for anti-tumor, preventing chemotherapy-induced neutropenia and preventing chemotherapy-induced myelosuppression. In the field of cancer treatment, the two derivatives provided by the application have lower toxic side effects under the similar therapeutic effect of plinabulin, have stronger therapeutic effect and higher therapeutic index under the similar toxic side effects, have similar ability of preventing neutropenia and lower toxic side effects compared with plinabulin, have better therapeutic effect than the combination of the commercialized white blood cell increasing drug Neulasta and plinabulin, and can significantly increase the number of various blood cells when combined with a chemotherapy drug. The derivatives provided by the application have wide application prospects in anti-tumor treatment, prevention of neutropenia and prevention of myelosuppression.

The application belongs to the field of textiles, and discloses a fabric for adjuvant therapy of breast cancer and a preparation method thereof. The preparation method comprises the following steps: firstly, preparing a fluorouracil FU and collagen tripeptide CTP compound FU-CTP, incorporating the compound into a core layer spinning solution, preparing a core-shell nanofiber membrane through electrospinning, and finally obtaining the fabric for adjuvant therapy of breast cancer. The fabric can release the compound FU-CTP in the form of micelles, CTP can carry FU, promote the transdermal penetration ability of FU, and enrich FU in the local breast to reach a therapeutic concentration, so that most side effects such as gastrointestinal side effects and bone marrow suppression caused by oral and intravenous administration of FU can be reduced.

This invention relates to the fields of biomedical engineering and drug delivery technology, specifically disclosing a novel targeted drug delivery system based on rosehip extracellular vesicles, comprising: preparing rosehip-derived extracellular vesicles; preparing drug-loaded vesicles; and preparing targeted modified drug-loaded vesicles. This invention utilizes the specific downregulation of stem cell-related pathways by rosehip components, while simultaneously leveraging doxorubicin to kill conventional tumor cells, forming a complementary therapeutic mechanism to fundamentally reduce the risk of tumor recurrence. The phenylboronic acid group of DSPE-PEG-PBA specifically recognizes sialic acid overexpressed on the surface of tumor cells, significantly increasing drug accumulation in tumor tissues while reducing distribution in normal tissues. By leveraging the natural biocompatibility and low immunogenicity of RHNVs, combined with the long-circulating properties of the PEG chain, systemic toxicity is minimized while ensuring delivery efficiency, particularly reducing the cardiotoxicity and bone marrow suppression of doxorubicin.

The invention relates to the technical field of blood protein polypeptides, in particular to a pig blood polypeptide with an effect of relieving myelosuppression as well as a preparation method and application of the pig blood polypeptide. The preparation method of the pig blood polypeptide comprises the following steps: carrying out enzymolysis on a mixture of pig blood globulin powder and water at 50-60 DEG C under the action of enzyme for 2-8 hours, and carrying out enzyme deactivation treatment; the enzyme comprises at least one of alkaline protease, papain and neutral protease. According to the preparation method of the pig blood polypeptide, the spray-dried blood cells are used as a raw material to prepare the pig blood polypeptide, so that the dependence of a traditional process on fresh pig blood is broken through, and secondary high-value utilization of the spray-dried blood cells is realized; the pig blood polypeptide provided by the invention can be used for relieving the myelosuppression effect induced by 5-FU.

The invention discloses a directional immunoregulation composition based on medicinal and edible substances and a preparation method thereof in the fields of functional foods, medical nutrition and massive health. The composition is prepared from the following raw materials in parts by weight through synergistic effects: 20-35 parts of astragalus membranaceus, 70-110 parts of Chinese yam, 2-8 parts of lucid ganoderma, 8-18 parts of fructus lycii and 8-18 parts of rhizoma polygonati. Through the synergistic effect of various medicinal and edible substances, immune indexes such as leukocytes and neutrophils can be directionally regulated and controlled, the myelosuppression symptom is effectively improved, meanwhile, the level of inflammatory factors such as serum IL-6 and CRP is reduced, the good anti-inflammatory regulation effect is achieved, the medicinal and edible substances are adopted as the raw materials, synergistic compatibility is scientific and reasonable, and the health-care food is suitable for being popularized and applied. The traditional Chinese medicine composition is suitable for long-term use.

The application provides a compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation is prepared from the following components in a mass fraction: 0.5-2.0 parts of paclitaxel powder with a purity of 99%, 18-30 parts of Herba Lysimachiae, 18-30 parts of Herba Impatientis, 18-30 parts of Radix Scrophulariae, 14-25 parts of Radix Curcumae, 14-25 parts of Radix Pini Strobil, 14-25 parts of Gynostemma pentaphyllum, 14-25 parts of Citrus medica, 10-18 parts of Radix Paeoniae Alba, 10-18 parts of Radix Paeoniae Rubra, 10-18 parts of Radix Rabdosiae, 6-12 parts of Fructus Schisandrae, 6-12 parts of Lumbricus, and 6-12 parts of Radix Glycyrrhizae. The compound paclitaxel broad-spectrum anticancer traditional Chinese medicine preparation can not only significantly inhibit the growth of tumor cells on a lung cancer patient, but also significantly reduce bone marrow suppression and immune function damage caused by paclitaxel.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.

The invention discloses an innovative application of pseudo-ginsenoside RT5 in preparation of leukocyte increasing drugs and tumor treatment support drugs. The medicine is used for treating or relieving myelosuppression leucopenia induced by chemotherapeutic medicines (such as etoposide). The invention creatively discovers that the pseudo-ginsenoside RT5 can remarkably improve the level of neutrophil caused by myelosuppression and effectively relieve the side effect of chemotherapy, and experiments prove that the pseudo-ginsenoside RT5 remarkably prolongs the survival time under the influence of chemotherapy drugs. The effectiveness of the method is analyzed based on an etoposide myelosuppression model and survival time of zebrafish fries. As the pseudo-ginsenoside RT5 is derived from a natural component of homology of medicine and food (such as American ginseng), the pseudo-ginsenoside RT5 has the advantages of high safety and suitability for long-term drug combination, the chemotherapy compliance and the curative effect can be remarkably improved, and a novel efficient and low-toxicity support drug is provided for overcoming myelosuppression in tumor chemotherapy.

The application provides an aurone compound and a medical use thereof, and is an aurone compound and application thereof in preparation of prevention and treatment of myelosuppression or blood system diseases. The aurone compound provided by the application can significantly improve the myelosuppression state caused by ruxolitinib and radiotherapy, can restore the generation of red blood cells after irradiation and use of ruxolitinib, and has a significant effect on the recovery of white blood cells, especially neutrophils and lymphocytes, of mice after irradiation. The application provides a new potential drug for the treatment of myelosuppression or blood system diseases.

The invention discloses application of crocetin and a cyclodextrin inclusion compound thereof in assisting in resisting tumors and relieving toxic and side effects in tumor treatment, belongs to the technical field of biological medicines, and particularly relates to application of crocetin or pharmaceutically acceptable salt thereof or combined administration of the cyclodextrin inclusion compound thereof and an anti-tumor chemotherapeutic drug to relieving toxic and side effects in tumor treatment. According to the crocetin cyclodextrin inclusion compound, the water solubility, the stability and the bioavailability of crocetin are remarkably improved. When the clathrate compound is combined with paclitaxel for use, the anti-tumor effect can be enhanced, and nervous system injury, myelosuppression and multi-organ toxicity caused by paclitaxel can be remarkably relieved. Experimental results show that the drug combination scheme shows the dual advantages of synergistic interaction and toxicity reduction in solid tumor models such as prostatic cancer and the like, and has important clinical application prospects.

The invention relates to the field of medicine, in particular to a bone marrow suppression early warning system in the tumor treatment period of children, which comprises a data acquisition module, a data processing module, a risk prediction module and a user interaction module, the data processing module is used for preprocessing various data acquired by the data acquisition module, the risk prediction module is used for calculating bone marrow suppression risk indexes of children and judging bone marrow suppression risks of the children according to the indexes, and the user interaction module is used for displaying prediction results of the risk prediction module. According to the scheme, retina image data and intestinal flora data are introduced in judgment of the myelosuppression risk, joint evaluation of the hematopoietic function state from the three levels of blood, microcirculation and micro-ecology is achieved not only depending on traditional hemogram indexes, the potential myelosuppression trend can be recognized earlier, early warning can be given out in advance, and the risk of myelosuppression can be judged. And the timeliness and accuracy of clinical intervention are improved.

A traditional Chinese medicine composition for treating myelosuppression during chemotherapy is prepared from the following traditional Chinese medicine materials in a weight ratio: 6-150 parts of raw astragalus, 2-50 parts of angelica, 2-50 parts of euphorbia humifusa, 2-50 parts of ligustrum lucidum, 2-50 parts of psoralea, and 2-30 parts of cuscuta. The traditional Chinese medicine composition can act on hematopoietic function through multiple components and multiple pathways, effectively improve myelosuppression caused by chemotherapy, and can be used to cooperate with chemotherapy, improve the completion rate of chemotherapy, and improve the quality of life during chemotherapy, with remarkable effects.

The invention discloses application of ackermania muciniphila in preparation of a medicine for relieving myelosuppression, and belongs to the technical field of biological medicine. The viable count of the Ackermania mucophila (AKK) is 1 * 10 < 5 >-1 * 10 < 12 > CFU / mL, and the invention also provides a pharmaceutical composition for relieving myelosuppression, which contains an effective dose of Ackermania mucophila and takes the Ackermania mucophila as an active ingredient; the pharmaceutical composition further comprises a pharmaceutically acceptable carrier which is selected from a diluent, a filler, a surfactant, an absorption enhancer, a disintegrating agent, a wetting agent and a dispersing agent, and the dosage form is selected from an injection, an emulsion, a tablet, powder, granules, gel, ointment, capsules or oral liquid and the like. Experiments prove that the AKK strain can remarkably relieve myelosuppression and promote short-term hematopoietic stem cell proliferation, and the high abundance of AKK is also related to low risk of severe myelosuppression, so that the AKK strain has a protective effect on myelosuppression and has an important clinical application value.